Announcements Trials
Browse Landscape

Status

Completed 85Unknown 32Recruiting 30Terminated 14Active not recruiting 6Withdrawn 5Not yet recruiting 5Suspended 1No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Multiple Myeloma 5Lambert-Eaton Myasthenic Syndrome 5Leukemia 4Carcinoma, Hepatocellular 4Precancerous Conditions 3Pheochromocytoma 3Neuroendocrine Tumors 3Myelodysplastic Syndromes 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Carcinoid Tumor 3Sarcoma, Ewing 2Sarcoma 2Paraganglioma 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Liver Neoplasms 2Immunoproliferative Disorders 2Immune System Diseases 2Hodgkin Disease 2Graft vs Host Disease 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × OTHER × Gastrointestinal Stromal Tumors × Clear all
NCT03493152 2025-05-28

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

The University of Texas Health Science Center at San Antonio

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡